There was a significant test for trend across all PPI dose categories, including nonusers (P < .001 for trend), al- though not among analyses confined only to different doses among users of PPIs, using the less than 0.75 pills/d category as the reference category (P = .22). Similar results were found for H2RA use, with a significant test for trend across all cat- egories of H2RA use (P < .001 for trend), although not among only users of H2RAs, using the less than 0.75 pills/d category as the reference category (P = .84 for trend).